Technical and commercial due diligence of antibody against metastatic cancers

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...
Learn More

Pre-DD on re-purposed ophthalmology product

Challenge: A private investment firm was interested in a European drug re-purposing company and asked Alacrita to perform top-level due diligence to help the firm decide whether it wanted to proceed...
Learn More

Due diligence for a microbiome therapeutic

Challenge: Our client, a mid-cap pharma, was planning to extend its portfolio in the gastrointestinal (GI) disease space. It was considering microbiome-based approaches, specifically live...
Learn More

Due diligence for in-licensing opportunities in oncology

Challenge: A lean pharma company reached out to Alacrita for due diligence support regarding three oncology assets of interest, prior to entering into licensing negotiations. The client requested an...
Learn More

Clinical due diligence of an NK cell therapy

Challenge: A leading NK cell research group had developed a novel process for manufacturing NK cells with highly differentiated properties. The technology had been licensed to a start-up company that...
Learn More

Internal DD and investor readiness for pre-clinical biotech company

Challenge: A late pre-clinical biotech company engaged in the development of antibody drug conjugates (ADCs) targeting GPCRs for treatment of solid tumors asked Alacrita to conduct an internal due...
Learn More

Valuation of deal for prophylactic mAbs against SARS-CoV-2

Challenge A recently emerged biotech company developing prophylactic monoclonal antibodies (mAbs) against a major viral target for immunocompromised patients asked Alacrita to develop an independent...
Learn More

Global sales forecast for a small molecule in hepatocellular carcinoma

Challenge A UK-based oncology drug development company was planning to in license a small molecule in development for hepatocellular carcinoma (HCC) and Rhabdomyosarcoma. Alacrita was commissioned to...
Learn More

Valuation of novel formulation of insulin for diabetes

Challenge A preclinical stage biotech company developing a novel formulation of insulin to treat diabetes mellitus was in discussions with prospective investors for a next round of funding. To...
Learn More

Valuation of a portfolio of therapeutics for an investment firm

Challenge An investment firm required independent valuations of five therapeutics within two of its portfolio companies, including four preclinical programs and a proprietary formulation of a...
Learn More

Valuation of a small molecule therapeutic for enhanced male infertility

Challenge A biotech company had developed preclinical data supporting the use of its lead drug candidate in enhancing male fertility. The product was being considered for both ex-vivo usage prior to...
Learn More

Oncology clinical expert input and asset valuation

Challenge A clinical stage immuno-oncology biotech company spun out from a leading university had completed a Phase I clinical trial in ovarian cancer patients with its lead antibody. In response to...
Learn More
Previous
1 2 3 4 5 ... 29
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.